Edward Feener
www.kalvista.com
0000-0003-1175-8469
KalVista Pharmaceuticals Inc
8 papers found
Refreshing results…
Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema
Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease
A mechanism for hereditary angioedema caused by a methionine-379–to–lysine substitution in kininogens
A mechanism for hereditary angioedema caused by a lysine 311–to–glutamic acid substitution in plasminogen
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema
Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation
Nomenclature of factor XI and the contact system
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
Missing publications? Search for publications with a matching author name.